{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:40:18Z","timestamp":1770460818442,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-022-03169-6","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T18:02:45Z","timestamp":1647021765000},"page":"2555-2566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of tacrolimus combined with corticosteroids in patients with idiopathic membranous nephropathy: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5158-876X","authenticated-orcid":false,"given":"Zhonghua","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"issue":"1","key":"3169_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.ajkd.2010.01.008","volume":"56","author":"RJ Glassock","year":"2010","unstructured":"Glassock RJ (2010) The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis 56(1):157\u2013167. https:\/\/doi.org\/10.1053\/j.ajkd.2010.01.008","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3169_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2215\/CJN.04321007","volume":"3","author":"FC Fervenza","year":"2008","unstructured":"Fervenza FC, Sethi S, Specks U (2008) Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 3(3):905\u2013919. https:\/\/doi.org\/10.2215\/CJN.04321007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3169_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM199307083290203","volume":"329","author":"A Schieppati","year":"1993","unstructured":"Schieppati A, Mosconi L, Perna A et al (1993) Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329(2):85\u201389. https:\/\/doi.org\/10.1056\/NEJM199307083290203","journal-title":"N Engl J Med"},{"issue":"2","key":"3169_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/kisup.2012.20","volume":"2","author":"The KDIGO Work Group","year":"2012","unstructured":"The KDIGO Work Group (2012) Chapter 7: Idiopathic membranous nephropathy. Kidney Int Suppl 2(2):186\u2013197. https:\/\/doi.org\/10.1038\/kisup.2012.20","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"3169_CR5","first-page":"100","volume":"35","author":"M Faurschou","year":"2008","unstructured":"Faurschou M, Sorensen IJ, Mellemkjaer L et al (2008) Malignancies in Wegener\u2019s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35(1):100\u2013105 (PMID: 17937462)","journal-title":"J Rheumatol"},{"issue":"5","key":"3169_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0890-6238(92)90004-d","volume":"6","author":"DR Plowchalk","year":"1992","unstructured":"Plowchalk DR, Mattison DR (1992) Reproductive toxicity of cyclophosphamide in the C57BL\/6N mouse: 1. Effects on ovarian structure and function. Reprod Toxicol 6(5):411\u2013421. https:\/\/doi.org\/10.1016\/0890-6238(92)90004-d","journal-title":"Reprod Toxicol"},{"issue":"4","key":"3169_CR7","first-page":"407","volume":"14","author":"J Berger","year":"1981","unstructured":"Berger J (1981) Changes in marrow myelopoietic and lymphoid cell counts after repeated cyclophosphamide administration in the rat. Haematologia (Budap) 14(4):407\u2013416 (PMID: 7344975)","journal-title":"Haematologia (Budap)"},{"issue":"4S","key":"3169_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4S):S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"issue":"7","key":"3169_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1517\/13543784.16.7.1099","volume":"16","author":"TH Westhoff","year":"2007","unstructured":"Westhoff TH, van der Giet M (2007) Tacrolimus in the treatment of idiopathic nephrotic syndrome. Expert Opin Investig Drugs 16(7):1099\u20131110. https:\/\/doi.org\/10.1517\/13543784.16.7.1099","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"3169_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/nep.12569","volume":"21","author":"R Ramachandran","year":"2016","unstructured":"Ramachandran R, Hn HK, Kumar V et al (2016) Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology (Carlton) 21(2):139\u2013146. https:\/\/doi.org\/10.1111\/nep.12569","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"3169_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","volume":"339","author":"M Chen","year":"2010","unstructured":"Chen M, Li H, Li XY et al (2010) Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci 339(3):233\u2013238. https:\/\/doi.org\/10.1097\/MAJ.0b013e3181ca3a7d","journal-title":"Am J Med Sci"},{"issue":"1","key":"3169_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312. https:\/\/doi.org\/10.1016\/0197-2456(95)00134-4","journal-title":"Control Clin Trials"},{"issue":"1","key":"3169_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jfma.2015.07.021","volume":"115","author":"L Peng","year":"2016","unstructured":"Peng L, Wei SY, Li LT et al (2016) Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy. J Formos Med Assoc 115(1):11\u201318. https:\/\/doi.org\/10.1016\/j.jfma.2015.07.021","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"3169_CR14","first-page":"9764","volume":"10","author":"QH Li","year":"2017","unstructured":"Li QH, Yang ZJ, Li L et al (2017) Comparison of efficacy and safety between tacrolimus and cyclosporine combined with corticosteroids in patients with idiopathic membranous nephropathy: a randomized controlled trial. Int J Clin Exp Med 10(6):9764\u20139770","journal-title":"Int J Clin Exp Med"},{"key":"3169_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000348475","volume":"181","author":"J Xu","year":"2013","unstructured":"Xu J, Zhang W, Xu Y et al (2013) Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial. Contrib Nephrol 181:152\u2013162. https:\/\/doi.org\/10.1159\/000348475","journal-title":"Contrib Nephrol"},{"issue":"4","key":"3169_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ekir.2017.02.004","volume":"2","author":"R Ramachandran","year":"2017","unstructured":"Ramachandran R, Yadav AK, Kumar V et al (2017) Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep 2(4):610\u2013616. https:\/\/doi.org\/10.1016\/j.ekir.2017.02.004","journal-title":"Kidney Int Rep"},{"issue":"3","key":"3169_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.5301\/jn.5000199","volume":"26","author":"L He","year":"2013","unstructured":"He L, Peng Y, Liu H et al (2013) Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. J Nephrol 26(3):564\u2013571. https:\/\/doi.org\/10.5301\/jn.5000199","journal-title":"J Nephrol"},{"issue":"2","key":"3169_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40265-016-0683-z","volume":"77","author":"LB Zhu","year":"2017","unstructured":"Zhu LB, Liu LL, Yao L et al (2017) Efficacy and safety of tacrolimus versus cyclophosphamide for primary membranous nephropathy: a meta-analysis. Drugs 77(2):187\u2013199. https:\/\/doi.org\/10.1007\/s40265-016-0683-z","journal-title":"Drugs"},{"key":"3169_CR19","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.2147\/DDDT.S209211","volume":"13","author":"W Lin","year":"2019","unstructured":"Lin W, Li HY, Lin S et al (2019) Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis. Drug Des Dev Ther 13:2179\u20132186. https:\/\/doi.org\/10.2147\/DDDT.S209211","journal-title":"Drug Des Dev Ther"},{"issue":"16","key":"3169_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12882-015-0199-x","volume":"4","author":"S Liu","year":"2015","unstructured":"Liu S, Li X, Li H et al (2015) Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study. BMC Nephrol 4(16):200. https:\/\/doi.org\/10.1186\/s12882-015-0199-x","journal-title":"BMC Nephrol"},{"issue":"4","key":"3169_CR21","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X20175976","volume":"50","author":"W Cui","year":"2017","unstructured":"Cui W, Lu X, Min X et al (2017) Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy. Braz J Med Biol Res 50(4):e5976. https:\/\/doi.org\/10.1590\/1414-431X20175976","journal-title":"Braz J Med Biol Res"},{"issue":"5","key":"3169_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/imj.14446","volume":"50","author":"H Zou","year":"2020","unstructured":"Zou H, Jiang F, Xu G (2020) Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy. Intern Med J 50(5):612\u2013619. https:\/\/doi.org\/10.1111\/imj.14446","journal-title":"Intern Med J"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03169-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03169-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03169-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T13:25:01Z","timestamp":1662729901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03169-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["3169"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03169-6","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflict of interest was reported in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}